Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.52 |
| ▸ | MMP3 | P08254 | 11/20 | 0.52 |
| ▸ | MMP13 | P45452 | 5/20 | 0.52 |
| ▸ | MMP7 | P09237 | 9/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.49 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14575007 | 0.84 | ALDH1A1 (0.61) | MMP1MMP3MMP13MMP7ADAM17 | |
| SCHEMBL6493434 | 0.84 | ALDH1A1 (0.61) | MMP1MMP3MMP13MMP7ADAM17 | |
| SCHEMBL6491614 | 0.84 | ALDH1A1 (0.61) | MMP1MMP3MMP13MMP7ADAM17 | |
| SCHEMBL4032000 | 0.84 | ALDH1A1 (0.61) | MMP1MMP3MMP13MMP7ADAM17 | |
| SCHEMBL4026464 | 0.82 | KMT2A (0.45) | MMP1MMP3MMP13MMP7ADAM17 | |
| SCHEMBL14574740 | 0.81 | MEN1 (0.45) | MMP1MMP3ADAM17MMP9MMP2 | |
| SCHEMBL6479660 | 0.81 | MEN1 (0.45) | MMP1MMP3ADAM17MMP9MMP2 | |
| SCHEMBL14575038 | 0.81 | ITGB1 (0.46) | MMP1MMP7ADAM17MMP9MMP2 | |
| SCHEMBL6490527 | 0.81 | TRPA1 (0.53) | MMP1MMP3MMP7ADAM17MMP9 | |
| SCHEMBL14574788 | 0.81 | TRPA1 (0.53) | MMP1MMP3MMP7ADAM17MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1452527-B1 | AZABICYCLO COMPOUND, MATRIX METALLOPROTEASE INHIBITOR, AND SKIN PREPARATION | SHISEIDO CO LTD (JP) | 2009-03-04 | — | — | EP | disclosed |
| US-7176217-B2 | Azabicyclo compound matrix metalloprotease inhibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176217-B2 | Azabicyclo compound matrix metalloprotease inhibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176217-B2 | Azabicyclo compound matrix metalloprotease inhibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050009808-A1 | Azabicyclo compound matrix metalloprotease inibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1452527-A1 | AZABICYCLO COMPOUND, MATRIX METALLOPROTEASE INHIBITOR, AND SKIN PREPARATION | Shiseido Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009808-A1 | Azabicyclo compound matrix metalloprotease inibitor and skin preparation | MMP1, MMP16, MMP9 | MMP1 1/4885MMP3 17/4885MMP13 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.